Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints BioSpaceOver the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) BioSpace Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Norgine gets first EU approval for WHIM syndrome therapyNext: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
